First patient achieved a confirmed partial response with 51.2% tumor regression with TCR-T cell persistence ongoing at 3 months post...
ATLANTA, GA, Sept. 21, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Springs Rejuvenation, Inc., formerly Avra, Inc. (OTC Pink: SPRJ),...
MIAMI, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for...
bioMérieux’s Solutions Aim to Improve Clinical Workflow and Deliver Actionable Data to Cross-functional Care Teams BIM graphic bioMérieux is listed...
JERUSALEM, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”), a leader in the...
Press release – No. 6 / 2022 Zealand Pharma Announces Oral Presentation of Phase 2 Data for BI 456906 at...
The Company’s first Phase 3 trial, OnPrime (GOG-3076), will evaluate Olvi-Vec, a modified vaccinia virus, as immunochemotherapyTrial will be conducted...
Expanded facilities illustrate MaxCyte’s commitment to Montgomery County and the state of Maryland, building the life sciences community, and propelling...
ZURICH, Switzerland, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology,...
NEW YORK, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company committed to enabling normal...
China CDE accepts Investigational New Drug (IND) application for lead gene therapy product candidate, FT-001, for the treatment of a...
CINCINNATI, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), a...
Ongoing program to focus on checkpoint inhibitor refractory patients following data presented at ASCO 2022 demonstrating 77% survival at a...
Four patents issued expanding claims related to delivery of nVNS and other therapies using mobile devicesROCKAWAY, N.J., Sept. 21, 2022...
The study evaluating a long-acting glatiramer acetate injection, GA Depot 40 mg once every four weeks, met the primary endpoint,...
Ernst & Young Orenda Corporate Finance Inc. (“EY”) engaged as independent financial advisorsTORONTO, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Acerus...
Data from Phase I/II trial of ATSN-101 in patients with GUCY2D-associated Leber congenital amaurosis (LCA1) to be presented DURHAM, N.C.,...
Vision enhancement company to present and discuss the impact of telehealth referrals for the legally blindCHICAGO, Sept. 20, 2022 (GLOBE...
Physician-led network offering complimentary skin cancer screenings across its network of clinics throughout OctoberMAITLAND, Fla., Sept. 20, 2022 (GLOBE NEWSWIRE)...
Published guidelines with highest evidence rating provide physicians confidence to adopt basivertebral nerve ablation as first-line treatmentMINNEAPOLIS, Sept. 20, 2022...